Chronic obstructive pulmonary disease (COPD) evidentiary framework

Ontario Health Technology Assessment Series

Volumn 12, Issue 2, 2012, Pages 1-97

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; INFLUENZA VACCINE; METHYLXANTHINE; MUCOLYTIC AGENT; NICOTINE DERIVATIVE; OXYGEN; PLACEBO; PNEUMOCOCCUS VACCINE; RESPIRATORY TRACT AGENT;

ABSENCE OF SIDE EFFECTS; AIR POLLUTION; ARTICLE; ASTHMA; CANADA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DUST; ECONOMIC EVALUATION; EVIDENCE BASED MEDICINE; EXERCISE; FEVER; FORCED EXPIRATORY VOLUME; FUME; HEADACHE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEREDITY; HUMAN; INCIDENCE; INDOOR AIR POLLUTION; INFLUENZA; INJECTION SITE PAIN; INJECTION SITE SWELLING; LUNG RESECTION; LUNG TRANSPLANTATION; MORTALITY; MYALGIA; NICOTINE REPLACEMENT THERAPY; OCCUPATIONAL EXPOSURE; OXIDATIVE STRESS; OXYGEN THERAPY; PATIENT COUNSELING; PATIENT PREFERENCE; PNEUMONIA; POSITIVE END EXPIRATORY PRESSURE; PREVALENCE; PULMONARY REHABILITATION; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RESPIRATORY TRACT INFECTION; RISK FACTOR; SCREENING TEST; SMOKING; SMOKING CESSATION; SPIROMETRY; SYSTEMATIC REVIEW; TELEHEALTH; TELEMONITORING; TOBACCO DEPENDENCE; TREATMENT OUTCOME; TUBERCULOSIS; VAPOR; BIOMEDICAL TECHNOLOGY ASSESSMENT; HOME CARE; INTEGRATED HEALTH CARE SYSTEM; ORGANIZATION AND MANAGEMENT; REVIEW; TELEMEDICINE;

DELIVERY OF HEALTH CARE, INTEGRATED; EVIDENCE-BASED MEDICINE; HOME CARE SERVICES; HUMANS; INFLUENZA VACCINES; OXYGEN INHALATION THERAPY; PNEUMOCOCCAL VACCINES; POSITIVE-PRESSURE RESPIRATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING CESSATION; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TELEMEDICINE;

EID: 84878253108     PISSN: 19157398     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease [Internet]. [place unknown]: Global Initiative for Chronic Obstructive Lung Disease, Inc.; 2010 [cited: 2011 Jul 6]. 97 p. Available from: http://www.goldcopd.org/uploads/users/files/GOLDReport_April112011.pdf
2. O'Donnell DE, Hernandez P, Kaplan A, Aaron S, Bourbeau J, Marciniuk D, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2008 update - highlights for primary care. Can Respir J. 2008 Jan;15 Suppl A:1A-8A.
3. Niewoehner DE. Clinical practice. Outpatient management of severe COPD. N Engl J Med. 2010 Apr 15;362(15):1407-16.
4. Donaldson GC, Wedzicha JA. COPD exacerbations.1: Epidemiology. Thorax. 2006 Feb;61(2):164-8.
5. Hurst JR, Donaldson GC, Quint JK, Goldring JJ, Baghai-Ravary R, Wedzicha JA. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009 Mar 1;179(5):369-74.
6. Chapman KR, Bourbeau J, Rance L. The burden of COPD in Canada: results from the Confronting COPD survey. Respir Med. 2003 Mar;97 Suppl C:S23-S31.
7. Public Health Agency of Canada. COPD [Internet]. [Ottawa (ON)]: Public Health Agency of Canada; [updated 2007 Nov 22; cited 2011 Jun 21]. Available from: http://www.phacaspc.gc.ca/publicat/2007/lbrdc-vsmrc/copd-mpoc-eng.php
8. Gershon AS, Wang C, Wilton AS, Raut R, To T. Trends in chronic obstructive pulmonary disease prevalence, incidence, and mortality in Ontario, Canada, 1996 to 2007: a populationbased study. Arch Intern Med. 2010 Mar 22;170(6):560-5.
9. Institute for Clinical Evaluative Sciences. Prevalence rate of chronic obstructive pulmonary disease (COPD) [Internet]. Toronto (ON): Institute for Clinical Evaluative Sciences; [updated 2011; cited 2011 Jun 12]. Available from: http://intool.ices.on.ca/Default.aspx
10. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007 Sep 1;370(9589):765-73.
11. Devereux G. ABC of chronic obstructive pulmonary disease. Definition, epidemiology, and risk factors. BMJ. 2006 May 13;332(7550):1142-4.
12. National Clinical Guideline Centre. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care [Internet]. London (U.K.): National Clinical Guideline Centre; 2010 [cited: 2011 Jun 6]. 673 p. Available from: http://www.nice.org.uk/nicemedia/live/13029/49425/49425.pdf
13. Editorial Board for Respiratory Disease in Canada. Respiratory disease in Canada [Internet]. [Ottawa (ON)]: Health Canada; 2001 [cited: 2011 Jun 12]. 118 p. Available from: http://www.phac-aspc.gc.ca/publicat/rdc-mrc01/pdf/rdc0901e.pdf
14. Statistics Canada. Leading causes of death [Internet]. Ottawa (ON): Statistics Canada; [updated 2007; cited 2011 Jul 7]. Available from: http://www.statcan.gc.ca/dailyquotidien/101130/dq101130b-eng.htm
15. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997 May 24;349(9064):1498-504.
16. Marciniuk DD, Goodridge D, Hernandez P, Rocker G, Balter M, Bailey P, et al. Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: a Canadian Thoracic Society clinical practice guideline. Can Respir J. 2011 Mar;18(2):69-78.
17. Medical Advisory Secretariat. Population-based smoking cessation strategies: a summary of a select group of evidence-based reviews. Ont Health Technol Assess Ser [Internet]. 2010 Jan; 10(1): 1-44. [cited: 2011 Jun 12]. Available from: http://www.hqontario.ca/en/mas/mas_ohtas_tech_smoking_20100120.html.
18. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007 Sep 1;370(9589):741-50.
19. Hill K, Goldstein RS, Guyatt GH, Blouin M, Tan WC, Davis LL, et al. Prevalence and underdiagnosis of chronic obstructive pulmonary disease among patients at risk in primary care. CMAJ. 2010;182(7):673-8.
20. Lin K, Watkins B, Johnson T, Rodriguez JA, Barton MB. Screening for chronic obstructive pulmonary disease using spirometry: summary of the evidence for the U.S. Preventative Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality; 2008 [cited: 2011 Jun 12]. Report No. 59. Available from: http://www.uspreventiveservicestaskforce.org/uspstf08/copd/copdes.pdf
21. U.S.Preventative Services Task Force. Screening for chronic obstructive pulmonary disease using spirometry: recommendation statement [Internet]. [updated 2008; cited 2011 Jun 22]. Available from: http://www.uspreventiveservicestaskforce.org/uspstf08/copd/copdrs.htm
22. Meyers BF, Patterson GA. Chronic obstructive pulmonary disease. 10: Bullectomy, lung volume reduction surgery, and transplantation for patients with chronic obstructive pulmonary disease. Thorax. 2003 Jul;58(7):634-8.
23. Tiong LU, Gibson PG, Hensley MJ, Hepworth R, Lasserson TJ, Smith B, Davies HRHR. Lung volume reduction surgery for diffuse emphysema. Cochrane Database Syst Rev 2006, Issue 4. Art. No.: CD001001. DOI: 10.1002/14651858.CD001001.pub2.
24. Benditt JO. Surgical options for patients with COPD: sorting out the choices. Respir Care. 2006 Feb;51(2):173-82.
25. Snider GL. Reduction pneumoplasty for giant bullous emphysema. Implications for surgical treatment of nonbullous emphysema. Chest. 1996 Feb;109(2):540-8.
26. Patel N, Criner GJ. Transplantation in chronic obstructive pulmonary disease. COPD. 2006 Aug;3(3):149-62.
27. Martinez FJ, Chang A. Surgical therapy for chronic obstructive pulmonary disease. Semin Respir Crit Care Med. 2005 Apr;26(2):167-91.
28. Review Manager (RevMan) [Computer program]. Version 5.1. Copenhagen (DK): The Nordic Cochrane Centre, The Cochrane Collaboration; 2011.
29. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004 Jun 19;328(7454):1490.
30. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005 Feb 15;142(4):233-9.
31. Puhan MA, Gimeno-Santos E, Scharplatz M, Troosters T, Walters EH, Steurer J. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011, Issue 10. Art. No.: CD005305. DOI: 10.1002/14651858.CD005305.pub3.
32. Puhan MA, Mador MJ, Held U, Goldstein R, Guyatt GH, Schunemann HJ. Interpretation of treatment changes in 6-minute walk distance in patients with COPD. Eur Respir J. 2008;32(3):637-43.
33. Holland AE, Hill CJ, Rasekaba T, Lee A, Naughton MT, McDonald CF. Updating the minimal important difference for six-minute walk distance in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil. 2010 Feb;91(2):221-5.